The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity

The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity

Cardiovascular (CV) toxicity from cancer therapy is a significant and growing concern. Conventional oncology clinical trial designs focused solely on cancer treatment efficacy have not provided sufficient information on both CV risk factors and outcomes. Similarly, traditional CV trials evaluating s...

Full description

Bibliographic Details
Main Authors: Lori M. Minasian, MD, Eileen Dimond, RN, MS, Myrtle Davis, DVM, PhD, ATS, Bishow Adhikari, PhD, Richard Fagerstrom, PhD, Carol Fabian, MD, Justin Floyd, DO, Joseph M. Unger, PhD, MS, Pamela S. Douglas, MD, Karen M. Mustian, PhD, MPH, Eric J. Chow, MD, MPH, Steven Lipshultz, MD, W. Gregory Hundley, MD, Saro H. Armenian, DO, MPH, Bonnie Ky, MD, MSCE
Format: Article
Language:English
Published: Elsevier 2019-09-01
Series:JACC. CardioOncology
Subjects:
adverse events
anthracyclines
cancer
cardioprotection
cardiotoxicity
chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666087319300298

Internet

http://www.sciencedirect.com/science/article/pii/S2666087319300298

Similar Items